文献リスト

1) 後藤信哉. 抗血栓療法ハンドブック. 東京: 中外医学社; 2011

2) Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrom-bosis. Eur Heart J. 2010; 31: 17-28

3) Gibson CM, Mega JL, Burton P, et al. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syn-drome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, dou-ble-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011; 161: 815-21. e6

4) Tamura N, Kitajima I, Kawamura Y, et al. Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions. Circ J. 2009; 73: 540-8

5) Hoshiba Y, Hatakeyama K, Tanabe T, et al. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. J Thromb Haemost. 2006; 4: 114-20

6) Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010; 74: 597-607

7) Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-60

8) Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996; 334: 1084-9

9) Takishita S, Kawazoe N, Yoshida T, et al. Ticlopidine and thrombocytopenia. N Engl J Med. 1990; 323: 1487-8

10) Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-associ-ated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007; 50: 1138-43

11) Fukuuchi Y, Tohgi H, Okudera T, et al. A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction. Cerebrovasc Dis. 2008; 25(1-2): 40-9

12) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348: 1329-39

13) Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the ʼmagic bulletʼ. Nat Rev Drug Discov. 2003; 2: 775-89

14) Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001; 409: 202-7

15) Goto S, Tamura N, Eto K, et al. Functional significance of adenosine 5ʼ-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation. 2002; 105: 2531-36

16) Savi P, Zachayus JL, Delesque-Touchard N, et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006; 103: 11069-74

17) Hardy AR, Conley PB, Luo J, et al. P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood. 2005; 105: 3552-60

18) Shiraga M, Miyata S, Kato H, et al. Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost. 2005; 3: 2315-23

19) Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-15

20) Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS random-ized trial. JAMA. 2011; 305(11): 1097-105

21) Goto S, Tamura N, Ishida H, et al. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adeno-sine 5ʼ-diphosphate receptor stimulation and cy-clic calcium signaling. J Am Coll Cardiol. 2006; 47: 155-62

22) Srinivasan S, Mir F, Huang JS, et al. The P2Y12 antagonists, 2-methylthioadenosine 5ʼ-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J Biol Chem. 2009; 284: 16108-17

23) Pampuch A, Cerletti C, de Gaetano G. Com-parison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost. 2006; 96: 767-73

24) Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003; 31: 53-9

25) Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003; 107: 32-7

26) Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical inter-action from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003; 108: 921-4

27) Saw J, Topol EJ. Lack of adverse clopidogrel-atorvastatin clinical interaction. Am J Cardiol. 2004; 93: 669; author reply 669-70

28) Mitsios JV, Papathanasiou AI, Rodis FI, et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation. 2004; 109: 1335-8

29) Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002; 30: 1288-95

30) Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84: 891-6

31) Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007; 5: 2429-36

32) Umemura K, Furuta T, Kondo K. The common gene variants of CYP2C19 affect pharmaco-kinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost. 2008; 6: 1439-41

33) 後藤信哉, 浅田祐士郎. 血栓症—やさしく, くわしく, わかりやすく. 東京: 南江堂; 2006

34) Gurbel PA, Serebruany VL. Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. J Thromb Thrombolysis. 2000; 10: 217-20

35) Sibbing D, Koch W, Gebhard D, et al. Cyto-chrome 2C19＊17 allelic variant, platelet aggre-gation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation. 2010; 121: 512-8

36) Kim IS, Jeong YH, Kang MK, et al. Correlation of high post-treatment platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y12 assay. J Thromb Thrombolysis. 2010; 30: 486-95

37) Geiger J, Brich J, Honig-Liedl P, et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol. 1999; 19: 2007-11

38) Voisin S, Bongard V, Tidjane MA, et al. Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay？ Role of hae-matocrit and haemoglobin levels. Thromb Haemost. 2011; 106: 227-9

39) Siller-Matula JM, Lang I, Christ G, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol. 2008; 52: 1557-63

40) Delavenne X, Mallouk N, Piot M, et al. Is there really a relationship between the plasma concen-tration of the active metabolite of clopidogrel and the results of platelet function tests？ J Thromb Haemost. 2010; 8: 2334-8

41) Bouman HJ, Parlak E, van Werkum JW, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness？ A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost. 2010; 8: 482-8

42) Bal Dit Sollier C, Berge N, Boval B, et al. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy. Thromb Haemost. 2009; 101: 116-22

43) Hamburg MA, Collins FS. The path to per-sonalized medicine. N Engl J Med. 2010; 363: 301-4

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp